Patients with advanced cancer have an elevated risk of venous thromboembolism. Increasingly, patients are admitted to palliative care settings for brief admissions, with greater numbers of discharges (vs deaths) reported internationally. There is limited guidance around the use of thromboprophylaxis or incidence of venous thromboembolism for these patients.
Aim:
The aim of this study was to review the use of thromboprophylaxis as well as incidence of venous thromboembolism and bleeding in palliative care units or residential hospices for patients with advanced cancer.
Design:
A systematic review using Cochrane methods.
Data sources:
Medline, Embase and the Cochrane Library were searched up to 28 September 2018 along with a grey literature search; the reference lists of selected papers were hand-searched. Inclusion criteria were original papers assessing thromboprophylaxis use in palliative care units or residential hospices for adult inpatients with cancer. Two reviewers independently selected and appraised papers using a tool designed for disparate data. Heterogeneity in study design made a meta-analysis not possible.
Results:
A total of 11 full-text papers (9 quantitative and 2 qualitative) and 11 abstracts were included. Thromboprophylaxis use ranged between 4% and 53%; venous thromboembolism rates between 0.5% and 20%; and bleeding incidence was between 0.01% and 9.8%. Risk assessment tools were used infrequently and adherence to international thromboprophylaxis guidelines ranged between 5% and 71%. Physician opinions differed around the use of thromboprophylaxis; patients were largely accepting of thromboprophylaxis if it was offered.
Conclusion:
There is limited evidence around the optimal use of thromboprophylaxis for patients with advanced cancer admitted to palliative care settings. Although some patients may derive benefit, further research in this area is warranted.
TrousseauA.Plegmasia alba dolens. In: TrousseauA (ed.) Lectures on clinical medicine, vol. 5. London: New Sydenham Society, 1865, pp. 281–332.
2.
AmbrusJLAmbrusCMMinkIB, et alCauses of death in cancer patients. J Med1975; 6(1): 61–64.
3.
BickRL.Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost1978; 5(1): 1–26.
4.
ChewHKWunTHarveyD, et alIncidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006; 166(4): 458–464.
5.
DonnellanEKhoranaAA.Cancer and venous thromboembolic disease: a review. Oncologist2017; 22: 199–207.
6.
CunninghamMSWhiteBO’DonnellJ.Prevention and management of venous thromboembolism in people with cancer: a review of the evidence. Clin Oncol2006; 18(2): 145–151.
7.
GeertsWHBergqvistDPineoGF, et alPrevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008; 133(Suppl. 6): 381S–453S.
8.
ShenVSPollakEW.Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?South Med J1980; 73(7): 841–843.
9.
LevitanNDowlatiARemickSC, et alRates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)1999; 78(5): 285–291.
10.
KudererNMCulakovaELymanGH, et alA validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist2016; 21(7): 861–867.
11.
BlomJWDoggenCJM. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2014; 293(6): 715–722.
12.
MandalaMFalangaARoilaF.Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol2011; 22(Suppl. 6): vi85–vi92.
13.
LymanGHBohlkeKKhoranaAA, et alVenous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol2015; 33(6): 654–656.
14.
NICE Clinical Guideline 92. Reducing the risk of thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. London: National Institute for Health and Clinical Excellence, 2015.
15.
LeeAY.The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Curr Opin Pulm Med2003; 9(5): 351–355.
16.
AklEABarbaMRohillaS, et alLow-molecular-weight heparins are superior to vitamin K antagonists for the long-term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res2008; 27(1): 21.
17.
RomeraACairolsMAVila-CollR, et alA randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg2009; 37(3): 349–356.
18.
PoschFKönigsbrüggeOZielinskiC, et alTreatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res2015; 136(3): 582–589.
19.
PrandoniPLensingAWPiccioliA, et alRecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Cancer2002; 100(10): 3484–3488.
20.
García EscobarIAntonio RebolloMGarcía AdriánS, et alSafety and efficacy of primary thromboprophylaxis in cancer patients. Clin Transl Oncol2017; 19(1): 1–11.
21.
NobleSPasiJ.Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer2010; 102(Suppl. 1): S2–S9.
22.
CarrierMKhoranaAAMorettoP, et alLack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med2014; 127(1): 82.e1–86.e1.
23.
BakitasMLyonsKDHegelMT, et alThe Project ENABLE II randomized controlled trial to improve palliative care for patients with advanced cancer. JAMA2009; 302(7): 741–749.
24.
TemelJSGreerJAMuzikanskyA, et alEarly palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med2010; 363(8): 733–742.
25.
ZimmermannCSwamiNKrzyzanowskaM, et alEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet (London, England)2014; 383(9930): 1721–1730.
26.
BrysonJCoeGSwamiN, et alAdministrative outcomes five years after opening an acute palliative care unit at a comprehensive cancer center. J Palliat Med2010; 13(5): 559–565.
27.
HuiDElsayemAPallaS, et alDischarge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med2010; 13(1): 49–57.
28.
HawkerSPayneSKerrC, et alAppraising the evidence: reviewing disparate data systematically. Qual Health Res2002; 12(9): 1284–1299.
NobleSIRFinlayIG. Have palliative care teams’ attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005. J Pain Symptom Manage2006; 32(1): 38–43.
31.
NobleSIRNelsonATurnerC, et alAcceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ2006; 332(7541): 577–580.
JohnsonMJMcMillanBFairhurstC, et alPrimary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms. J Pain Symptom Manage2014; 48(1): 56–64.
34.
KiernerKAGartnerVSchwarzM, et alUse of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation. Am J Hosp Palliat Care2008; 25(2): 127–131.
35.
GartnerVKiernerKANamjeskyA, et alThromboprophylaxis in patients receiving inpatient palliative care: a survey of present practice in Austria. Support Care Cancer2012; 20(9): 2183–2187.
36.
LegaultSTierneySSénécalI, et alEvaluation of a thromboprophylaxis quality improvement project in a palliative care unit. J Pain Symptom Manage2011; 41(3): 503–510.
37.
WeberCMerminodTHerrmannFR, et alProphylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer2008; 16(7): 847–852.
38.
PautexSJammeSVayne-BossertP, et alRecent pulmonary embolism at autopsy and prophylactic anticoagulation. Palliat Med2012; 26(4): 498.
39.
TardyBChapelleCPicardS, et alMajor and non-major clinically relevant bleeding in patients hospitalized in palliative care units: results of a French multicentre observational study. J Thromb Haemost2015; 13: 547.
40.
GillonSNobleSWardJ, et alPrimary thromboprophylaxis for hospice inpatients: who needs it?Palliat Med2011; 25(7): 701–705.
41.
ThorleyFJonesHLoweJ, et alA regional audit of pharmacological venous thromboprophylaxis in palliative medicine. Palliat Med2016; 30(4): S67–S68.
42.
ThomasSShipleyLGledhillR, et alAssessment and prescription of venous thromboembolism prophylaxis in a hospice setting. Palliat Med2016; 30(4): S80.
43.
JohnsonMJSheardLNobleS, et alTo be or not to be? Primary thromboprophylaxis in people with advanced cancer: views of oncologists and palliative physicians. Palliat Med2012; 26(4): 522.
44.
McMullanDDohertyJCochraneB, et alVenous thromboembolism prophylaxis in specialist palliative care units in Northern Ireland. Palliat Med2012; 26(4): 596–597.
45.
BrabinETDouglasEMackayC, et alThe role of primary thromboprophylaxis in hospice patients: a retrospective review of current practice. Palliat Med2008; 22(Suppl. 2): 569–603.
46.
CiuhuANPopescuMRadoiM, et alChallenges and directions in anticoagulation in palliative care of cancer patients. Palliat Med2016; 30(6): NP262.
47.
BertolaASaberBValleA, et alAnti-co: antithrombotic approach in the palliative care setting: a retrospective study. Palliat Med2014; 28(6): 730–731.
48.
Alt-EppingBKanzowGEwaldH, et alIndicating anticoagulant therapy in palliative care – a multicenter survey. Palliat Med2010; 1: S137.
49.
ChanthongPAmigoPHRixS, et alUse of anticoagulants and prevalence of venous thromboembolism (VTE) in a tertiary palliative care unit. Support Care Cancer2011; 1: S222–S223.
50.
Vayne-BossertPTaniaTZulianG.Prophylactic anticoagulation at the end-of-life, analysis of local practice. Palliat Med2018; 32(Suppl. 1): 85.
51.
Garzon-RodriguezCPorta-SalesJManas-IzquierdoV, et alThromboembolic disease in the advanced cancer patient: incidence, complications, primary thromboprophylaxis and patient perception [Enfermedad tromboembolica en el paciente oncologico avanzado: incidencia, complicaciones, tromboprofilaxis]. Med Paliativa2015; 22(2): 52–59.
52.
SamamaMMCohenATDarmonJY, et alA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med1999; 341(11): 793–800.
53.
CohenAT.Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ2006; 332(7537): 325–329.
54.
LeizoroviczA.Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004; 110(7): 874–879.
55.
GussoniGFrassonSLa ReginaM, et alThree-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer: findings from the RIETE registry. Thromb Res2013; 131(1): 24–30.
56.
ZwickerJIRojanACampigottoF, et alPattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol2014; 32(17): 1792–1796.
BachMBauersachsR.Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE. Thromb Haemost2016; 116(Suppl. 2): S24–S32.
60.
ShortNJConnorsJM.New oral anticoagulants and the cancer patient. Oncologist2014; 19(1): 82–93.
61.
SchmaierAAAmbeshPCampiaU.Venous thromboembolism and cancer. Curr Cardiol Rep2018; 20(10): 89.
62.
KhoranaAAKudererNMCulakovaE, et alDevelopment and validation of a predictive model for chemotherapy-associated thrombosis. Clin Trials Obs2008; 111(10): 4902–4908.
63.
AyCDunklerDMarosiC, et alPrediction of venous thromboembolism in cancer patients. Blood2011; 116(24): 5377–5382.
64.
GerotziafasGTTaherAAbdel-RazeqH, et alA predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated thrombosis study. Oncologist2017; 22: 1222–1231.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
